Grafa logo

Axsome targets durable fibromyalgia relief with Phase 3 launch for AXS-14

Written by Brie CarterPublished jan. 15 2026Last Updated jan. 15 2026

Share

Axsome Therapeutics (NASDAQ:AXSM) announced on Thursday that it has dosed the first patient in its FORWARD Phase 3 clinical trial, a pivotal step in the development of AXS-14 (esreboxetine) for the management of fibromyalgia.

The trial focuses on the durability of the drug's effect, addressing a massive unmet need for the 17 million Americans suffering from the chronic neurological pain disorder.

AXS-14 is a highly selective and potent norepinephrine reuptake inhibitor (NRI).

By targeting the central nervous system's noradrenergic pathways, the therapy aims to modulate the "pain gates" that lead to the widespread pain, fatigue, and cognitive "fibro fog" characteristic of the condition.

The FORWARD trial (Fibromyalgia Response with Esreboxetine Evaluated Using a Randomized Withdrawal Research Design) utilizes a sophisticated two-stage structure to measure how well the drug maintains its benefits over time.

While all participants receive AXS-14 (8 mg once daily) for 12 weeks to identify those who respond positively to the medication, patients who achieved a treatment response are then randomized 1:1 to either continue the 8 mg dose or switch to a placebo for an additional 12 weeks.

The primary endpoint is the time to loss of therapeutic response.

This design specifically filters for patients who benefit from the drug, then tests whether withdrawing that treatment leads to a return of symptoms compared to those who stay on the therapy.

The initiation of the FORWARD trial follows a strategic pivot for Axsome.

After receiving a "Refusal to File" letter from the FDA in 2025 regarding a previous application, the company worked with regulators to design this Phase 3 study to provide the robust durability data required for approval.

Axsome enters 2026 with significant momentum; the company recently reported preliminary 2025 revenues exceeding analyst expectations, driven by the commercial success of its depression treatment, Auvelity.

If the FORWARD trial meets its primary endpoint, AXS-14 could become the fourth FDA-approved product in Axsome's growing central nervous system portfolio.